Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

The Effect of CYP2D6/3A5 Genotypes on Plasma Concentrations of Haloperidol after Adjunctive Treatment of Aripiprazole

  • Shim, Joo-Cheol (Department of Psychiatry, School of Medicine, Inje University) ;
  • Ahn, Jung-Mi (IGONGGAM Child Mental Health Clinic) ;
  • Jung, Do-Un (Department of Psychiatry, School of Medicine, Inje University) ;
  • Kong, Bo-Geum (Department of Psychiatry, School of Medicine, Inje University) ;
  • Kang, Jae-Wook (Department of Psychiatry, School of Medicine, Inje University) ;
  • Liu, Kwang-Hyeon (Department of Clinical Pharmacology, Clinical Trial Center and Pharmacogenomic Research Center, School of Medicine, Inje University) ;
  • Shin, Jae-Gook (Department of Clinical Pharmacology, Clinical Trial Center and Pharmacogenomic Research Center, School of Medicine, Inje University)
  • Received : 2010.11.21
  • Accepted : 2011.02.01
  • Published : 2011.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives To evaluate the drug interactions between aripiprazole and haloperidol, authors investigated plasma concentrations of those drugs by genotypes. Method Fifty six patients with a confirmed Diagnostic and Statistical Manual of Mental Disorders 4th edition diagnosis of schizophrenia were enrolled in this eight-week, double blind, placebo-controlled study. Twenty-eight patients received adjunctive aripiprazole treatment and twenty-eight patients received placebo while being maintained on haloperidol treatment. Aripiprazole was dosed at 15 mg/day for the first 4 weeks, and then 30 mg for the next 4 weeks. The haloperidol dose remained fixed throughout the study. Plasma concentrations of haloperidol and aripiprazole were measured by high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) at baseline, week 1, 2, 4 and 8. $^*1$, $^*5$, and $^*10$ B alleles of CYP2D6 and $^*1$ and $^*3$ alleles of CYP3A5 were determined. The Student's T-test, Pearson's Chi-square test, Wilcoxon Rank Sum test and Logistic Regression analysis were used for data analysis. All tests were two-tailed and significance was defined as an alpha < 0.05. Results In the frequency of CYP2D6 genotype, $^*1/^*10$ B type was most frequent (36.5%) and $^*1/^*1$ (30.8%), $^*10B/^*10B$ (17.3%) types followed. In the frequency of CYP3A5 genotype, $^*3/^*3$ type was found in 63.5% of subjects, and $^*1/^*3$ type and $^*1/^*1$ were 30.8% and 5.8% respectively. The plasma levels of haloperidol and its metabolites did not demonstrate significant time effects and time-group interactions after adjunctive treatment of aripiprazole. The genotypes of CYP2D6 and 3A5 did not affect the plasma concentration of haloperidol in this trial. No serious adverse event was found after adding aripiprazole to haloperidol. Conclusion No significant drug interaction was found between haloperidol and aripiprazole. Genotypes of CYP2D6 and 3A5 did not affect the concentration of haloperidol after adding aripiprazole.

Keywords

References

  1. Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olie JP, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol 2006;29:28-33. https://doi.org/10.1097/00002826-200601000-00009
  2. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18:375- 383. https://doi.org/10.1177/026988110401800308
  3. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771. https://doi.org/10.4088/JCP.v63n0903
  4. Cada DJ, Levien T, Baker DE. Aripiprazole. Hospital Pharmacy 2003;38:247-256. https://doi.org/10.1177/001857870303800308
  5. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715- 1736. https://doi.org/10.2165/00003495-200464150-00010
  6. Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry 2006;67: 675-676. https://doi.org/10.4088/JCP.v67n0420d
  7. Keller Ashton A. Indexing of reports on aripiprazole augmentation of clozapine. J Clin Psychiatry 2007;68:334-335; author reply 335.
  8. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:843-853. https://doi.org/10.4088/JCP.v68n0604
  9. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66: 1216-1220. https://doi.org/10.4088/JCP.v66n1002
  10. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic- induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164:1404-1410. https://doi.org/10.1176/appi.ajp.2007.06071075
  11. Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet 2005;20:55-64. https://doi.org/10.2133/dmpk.20.55
  12. Citrome L, Macher JP, Salazar DE, Mallikaarjun S, Boulton DW. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol 2007;27:279-283. https://doi.org/10.1097/jcp.0b013e318056f309
  13. Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006;28:744-749. https://doi.org/10.1097/01.ftd.0000249944.42859.bf
  14. Kuo J, Hwu HG. Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient. Clin Neuropharmacol 2008;31:173-175. https://doi.org/10.1097/WNF.0b013e318123ee01
  15. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9:410-418. https://doi.org/10.2174/138920008784746373
  16. Kubo M, Mizooku Y, Hirao Y, Osumi T. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005;822:294-299. https://doi.org/10.1016/j.jchromb.2005.06.023
  17. Hempenius J, Steenvoorden RJ, Lagerwerf FM, Wieling J, Jonkman JH. 'High throughput' solid-phase extraction technology and turbo ionspray LC-MS-MS applied to the determination of haloperidol in human plasma. J Pharm Biomed Anal 1999;20:889-898. https://doi.org/10.1016/S0731-7085(99)00107-7
  18. Hoja H, Marquet P, Verneuil B, Lotfi H, Dupuy JL, Pénicaut B, et al. Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization. J Chromatogr B Biomed Sci Appl 1997;688:275- 280. https://doi.org/10.1016/S0378-4347(96)00294-0
  19. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005;33:884-887. https://doi.org/10.1124/dmd.105.003822
  20. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999;9:669-682. https://doi.org/10.1097/01213011-199912000-00002
  21. Johansson I, Oscarson M, Yue QY, Bertilsson L, SjOqvist F, Ingelman- Sundberg M. Genetic analysis of the Chinese cytochrome P45- 02D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-459.
  22. Nikoloff D, Shim JC, Fairchild M, Patten N, Fijal BA, Koch WH, et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J 2002;2:400-407. https://doi.org/10.1038/sj.tpj.6500138
  23. Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim JW. Sequencebased CYP2D6 genotyping in the Korean population. Ther Drug Monit 2006;28:382-387. https://doi.org/10.1097/01.ftd.0000211823.80854.db
  24. Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and $CYP2D6^{\ast}10$ genotype of Korean subjects. Clin Pharmacol Ther 2000;67:567-576. https://doi.org/10.1067/mcp.2000.106128
  25. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004;44:1083-1105. https://doi.org/10.1177/0091270004268128
  26. Darby JK, Pasta DJ, Dabiri L, Clark L, Mosbacher D. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1995;15:334-340. https://doi.org/10.1097/00004714-199510000-00005
  27. Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006;28:744-749. https://doi.org/10.1097/01.ftd.0000249944.42859.bf
  28. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993;218:585-595. https://doi.org/10.1111/j.1432-1033.1993.tb18412.x
  29. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-779. https://doi.org/10.1097/00008571-200112000-00005
  30. Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 2007;40:107-110. https://doi.org/10.1055/s-2007-977715
  31. Travis MJ, Burns T, Dursun S, Fahy T, Frangou S, Gray R, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005;59:485-495. https://doi.org/10.1111/j.1368-5031.2005.00498.x
  32. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004;55:491-493. https://doi.org/10.1176/appi.ps.55.5.491